Reducing the risk of COVID-19 in research that involves interrupting ART

Simon Collins, HIV i-Base

These two papers, published as letters in JAIDS, discuss ways to reduce risks to participants in cure-related studies that involve a treatment interruption.

Some earlier studies were rightly put on hold during the early pandemic but wider availability of vaccines have enabled many of these studies to now reopen.


  1. Peluso ML et al. SARS-CoV-2 booster vaccination for participants in “HIV cure”-related clinical trials. JAIDS. Letter. doi: 10.1097/QAI.0000000000002875. (26 November 2021).
  2. Peluso ML et al. SARS-CoV-2 Vaccination in the context of ongoing HIV cure-related research studies. JAIDS JAIDS. Letter, 87(4)e232-e233. doi: 10.1097/QAI.0000000000002690. (1 August 2021).

Links to other websites are current at date of posting but not maintained.